Adenosine derivative and pharmaceutical composition comprising the same

Abstract

Disclosed here is an adenosine derivative prodrug that can have reverse transcriptase inhibitor activity in vivo. This disclosure is also directed to a pharmaceutical composition comprising the adenosine derivative that can be used for the treatment of HIV infection or RNA virus infection.

1 - 59 . (canceled) 
     
     
         60 . A compound of formula 4-A, or a pharmaceutically acceptable salt or stereoisomer thereof: 
       
         
           
           
               
               
           
         
       
       . 
     
     
         61 . The compound of  claim 60 . 
     
     
         62 . The pharmaceutically acceptable salt of  claim 60 . 
     
     
         63 . The stereoisomer of  claim 60 . 
     
     
         64 . A compound which is ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl ((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl) carbonate. 
     
     
         65 . A pharmaceutical composition comprising the compound of  claim 61  and a pharmaceutically acceptable carrier. 
     
     
         66 . A pharmaceutical composition comprising the compound of  claim 62  and a pharmaceutically acceptable carrier. 
     
     
         67 . A pharmaceutical composition comprising the compound of  claim 64  and a pharmaceutically acceptable carrier. 
     
     
         68 . The pharmaceutical composition of  claim 65 , wherein the pharmaceutical composition is a liquid dosage form suitable for oral administration. 
     
     
         69 . The pharmaceutical composition of  claim 65 , wherein the pharmaceutical composition is a solid dosage form suitable for oral administration. 
     
     
         70 . The pharmaceutical composition of  claim 66 , wherein the pharmaceutical composition is a liquid dosage form suitable for oral administration. 
     
     
         71 . The pharmaceutical composition of  claim 66 , wherein the pharmaceutical composition is a solid dosage form suitable for oral administration. 
     
     
         72 . The pharmaceutical composition of  claim 67 , wherein the pharmaceutical composition is a liquid dosage form suitable for oral administration. 
     
     
         73 . The pharmaceutical composition of  claim 67 , wherein the pharmaceutical composition is a solid dosage form suitable for oral administration.